ichorbio Citations (Resources)

The efficacy of therapeutic monoclonal antibodies (mAbs) in oncology often hinges on their ability to engage innate immune effector cells, primarily Natural Killer (NK) cells and macrophages, through the Fc gamma receptor IIIa (CD16a). This engagement triggers...

A recent article published in Nature (Vol. 631, 23 July 2025) reveals that antibody-mediated humoral immunity, specifically the presence of autoantibodies (AAbs), can significantly influence the effectiveness of checkpoint immunotherapy (CPI) for cancer. The study, which used a high-throughput...

A recent study published in 

Molecular Therapy: Oncology (Vol. 33, Sept 2025) demonstrates the therapeutic potential of a novel oncolytic vaccinia...

Introduction...

Introduction

Dietary fiber has long been heralded as a health-promoting nutrient, with recent studies suggesting it may enhance the efficacy of immune checkpoint blockade (ICB) therapies by modulating the gut microbiome. However...

Introduction

Despite advances in immunotherapy, relapse remains a major hurdle in B-cell malignancies, particularly due to immune evasion through antigen loss. While CD19- and CD20-targeted immunotherapies have transformed treatment paradigms, they are prone...